It is our obligation to identify patients who may be eligible for precision-based therapies. Failing to test for appropriate biomarkers could result in lost opportunities for significantly improved outcomes.
Location
Tallahassee, Florida, USA
By the numbers
40 years of experience in urology
1 clinical trial led
2 peer-reviewed publications focused on prostate cancer
It is our obligation to identify patients who may be eligible for precision-based therapies. Failing to test for appropriate biomarkers could result in lost opportunities for significantly improved outcomes.
About Dr Scott Sellinger
Dr Scott Sellinger is a practicing urologist and the President of Advanced Urology Institute (AUI), one of the largest independent urology practices in the United States. He is widely recognized for his leadership in operationalizing advanced prostate cancer (APC) care in independent urology settings. He serves as Director of Advanced Prostate Cancer clinics at AUI and also chairs AUI’s APC Committee, and currently sits on the board of directors.
Beyond his clinical leadership, Dr Sellinger has held prominent roles in professional associations, including President of the American Association of Clinical Urologists, the Southeastern Section of the American Urological Association and the Florida Urological Society. He currently serves as President of the Large Urology Group Practice Association (LUGPA), representing over 2,300 urologists across the US in efforts to protect and advance independent, physician-directed urology.
In addition to his urology-specific work, Dr Sellinger has a longstanding interest in risk management and prevention of medical errors, and has lectured extensively on these topics nationally and internationally.
Key areas of interest
- Advancing precision-driven treatment options for advanced prostate cancer
- Prostate cancer education for urologists, oncologists and advanced practice providers
- Improving identification of prostate cancer patients who are eligible for advanced therapies
Dr Scott Selinger has been compensated by AstraZeneca for their time and expertise in contributing to this initiative.
Explore key pages
AKT, protein kinase B; mHSPC, metastatic hormone-sensitive prostate cancer; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homolog.
